Placebo response in asthma: a robust and objective phenomenon

Area of Science:

• Pulmonary Medicine
• Psychoneuroimmunology
• Clinical Pharmacology

Background:

• Placebos are hypothesized to improve medical conditions by enhancing patient expectations.
• Evidence suggests placebo benefits may be limited to subjective outcomes, with questions about objective physiological effects.
• Despite this, mind-body connections and placebo effects in asthma are widely acknowledged.

Purpose of the Study:

• To investigate if placebo can reduce airway hyperreactivity in asthma patients.
• To quantify the magnitude of the placebo effect.
• To identify predictors of placebo response and assess physician influence on it.

Main Methods:

• A randomized, double-blind, crossover study involving 55 asthma patients.
• Patients underwent serial methacholine challenges after receiving placebo or salmeterol.
• Physician interactions were manipulated to convey positive or neutral expectancies.

Main Results:

• Placebo administration significantly reduced bronchial hyperreactivity compared to baseline.
• The concentration of methacholine needed to cause a 20% decrease in FEV(1) nearly doubled with placebo.
• Eighteen percent of subjects were classified as placebo responders; physician communication did not affect the placebo response.

Conclusions:

• Objective placebo effects are demonstrable in asthma, showing clinically significant magnitude.
• These findings highlight the importance of placebo responses in asthma research and therapy.
• The study indicates that physician communication did not modulate the placebo effect in this context.